Chrysos Corporation reports a robust Q2 FY25 with a 12% quarter-on-quarter and 53% year-on-year revenue increase, driven by expanding international sales and rising sample volumes. The company secured two new contracts, boosting its PhotonAssay™ footprint and maintaining strong financial health.
Mesoblast has raised A$260 million through a global private placement to fund the US commercial launch of its FDA-approved cell therapy Ryoncil® and accelerate clinical development in chronic low back pain.
Syrah Resources has been awarded a US$165 million tax credit under the US Inflation Reduction Act to support the expansion of its Vidalia active anode material facility in Louisiana, potentially increasing production capacity to 45ktpa.